Evidence map›Paper›PMID 35184552›Full record

ArticleACS infectious diseases2022

Synthesis and

Lu Lu, Linda Åkerbladh, Shabbir Ahmad, Vivek Konda, Sha Cao, Anthony Vocat, Louis Maes, Stewart T Cole, Diarmaid Hughes, Mats Larhed and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. STOP Strategy to InhibitAntibiotics (Basel, Switzerland) · 2025
    Article
  3. Reactions ofInternational journal of molecular sciences · 2025
    Article
  4. Inhibitors of Type II NADH Dehydrogenase Enzyme: A Review.Current protein & peptide science · 2025
    Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Lu LuDepartment of Cell and Molecular Biology, BMC, Uppsala University, Box 596, SE-751 24 Uppsala, Sweden.
Linda ÅkerbladhDepartment of Medicinal Chemistry, Organic Pharmaceutical Chemistry, BMC, Uppsala University, Box 574, SE-751 23 Uppsala, Sweden.
Shabbir AhmadDepartment of Cell and Molecular Biology, BMC, Uppsala University, Box 596, SE-751 24 Uppsala, Sweden.
Vivek KondaDepartment of Medicinal Chemistry, Organic Pharmaceutical Chemistry, BMC, Uppsala University, Box 574, SE-751 23 Uppsala, Sweden.
Sha CaoDepartment of Medical Biochemistry and Microbiology, BMC, Uppsala University, Box 582, SE-751 23 Uppsala, Sweden.
Anthony VocatÉcole Polytechnique Fédérale de Lausanne, EPFL SV/GHI/UPCOL, Global Health Institute, Station no. 19, CH-1015 Lausanne, Switzerland.
Louis MaesLaboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, B-2610 Antwerp, Belgium.
Stewart T ColeÉcole Polytechnique Fédérale de Lausanne, EPFL SV/GHI/UPCOL, Global Health Institute, Station no. 19, CH-1015 Lausanne, Switzerland.
Diarmaid HughesDepartment of Medical Biochemistry and Microbiology, BMC, Uppsala University, Box 582, SE-751 23 Uppsala, Sweden.
Mats LarhedDepartment of Medicinal Chemistry, Science for Life Laboratory, BMC, Uppsala University, Box 574, SE-751 23 Uppsala, Sweden.ORCID 0000-0001-6258-0635
Peter BrandtDepartment of Medicinal Chemistry, Organic Pharmaceutical Chemistry, BMC, Uppsala University, Box 574, SE-751 23 Uppsala, Sweden.
Anders KarlénDepartment of Medicinal Chemistry, Organic Pharmaceutical Chemistry, BMC, Uppsala University, Box 574, SE-751 23 Uppsala, Sweden.
Sherry L MowbrayDepartment of Cell and Molecular Biology, BMC, Uppsala University, Box 596, SE-751 24 Uppsala, Sweden.ORCID 0000-0002-0732-6367
Uppsala University · SEÉcole Polytechnique Fédérale de Lausanne · CHUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type II NADH dehydrogenase (NDH-2) is an essential component of electron transfer in many microbial pathogens but has remained largely unexplored as a potential drug target. Previously, quinolinyl pyrimidines were shown to inhibit

Indexed as

Mycobacterium tuberculosisNADH DehydrogenaseMicrobial Sensitivity TestsNADPyrimidinesNADNADH DehydrogenasePyrimidinesantimicrobialsESKAPE pathogensNDH-2quinolinyl pyrimidinestuberculosis

Identifiers

PMID35184552
PMCPMC8922281
OpenAlexW2766243659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.